Opportunities in somatostatin research: Biological, chemical and therapeutic aspects

被引：465

作者：

Weckbecker, G ^{[1
]}

Lewis, I ^{[1
]}

Albert, R ^{[1
]}

Schmid, HA ^{[1
]}

Hoyer, D ^{[1
]}

Bruns, C ^{[1
]}

机构：

[1] Novartis Pharma AG, Novartis Inst Biomed Res, Transplantat & Immunol, CH-4002 Basel, Switzerland

来源：

NATURE REVIEWS DRUG DISCOVERY | 2003年 / 2卷 / 12期

关键词：

D O I：

10.1038/nrd1255

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Somatostatins - also known as somatotropin-release inhibiting factors (SRIFs) - are a family of cyclopeptides that have broad inhibitory effects on the secretion of hormones such as growth hormone, insulin and glucagon. These effects have formed the basis for the clinical use of SRIF analogues in the treatment of acromegaly and endocrine tumours. The discovery of the five SRIF receptor subtypes in the 1990s further enhanced our understanding of the biological roles of SRIFs, and paved the way for new therapeutic opportunities. Here we review recent advances in SRIF biology, the chemistry of SRIF agonists and antagonists, and the therapeutic potential of such compounds in a wide range of established and novel indications.

引用

页码：999 / 1017

页数：19

共 226 条

[21] SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile [J].

Bruns, C ;

Lewis, I ;

Briner, U ;

Meno-Tetang, G ;

Weckbecker, G .

EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2002, 146 (05) :707-716

[22] MOLECULAR PHARMACOLOGY OF SOMATOSTATIN-RECEPTOR SUBTYPES [J].

BRUNS, C ;

WECKBECKER, G ;

RAULF, F ;

KAUPMANN, K ;

SCHOEFFTER, P ;

HOYER, D ;

LUBBERT, H .

MOLECULAR AND CELL BIOLOGICAL ASPECTS OF GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR DISEASE, 1994, 733 :138-146

[23] Somatostatin receptors and the potential use of Sandostatin® to interfere with vascular remodelling [J].

Bruns, C ;

Shi, V ;

Hoyer, D ;

Schuurman, H ;

Weckbecker, G .

EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2000, 143 :S3-S7

[24]

BRUNS C, 1996, METAB CLIN EXP, V44, P17

[25]

BRUNS C, 2001, END SOC 83 ANN M DEN

[26] Vitreous levels of IGF-I, IGF binding protein 1, and IGF binding protein 3 in proliferative diabetic retinopathy -: A case-control study [J].

Burgos, R ;

Hernández, C ;

Mateo, C ;

Mesa, J ;

Cantón, A ;

Simó, R .

DIABETES CARE, 2000, 23 (01) :80-83

[27] PREVENTION OF THE DAWN PHENOMENON (EARLY MORNING HYPERGLYCEMIA) IN INSULIN-DEPENDENT DIABETES-MELLITUS BY BEDTIME INTRANASAL ADMINISTRATION OF A LONG-ACTING SOMATOSTATIN ANALOG [J].

CAMPBELL, PJ ;

BOLLI, GB ;

GERICH, JE .

METABOLISM-CLINICAL AND EXPERIMENTAL, 1988, 37 (01) :34-37

[28] Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide [J].

Caron, P ;

MorangeRamos, I ;

Cogne, M ;

Jaquet, P .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (01) :18-22

[29]

CASCINU S, 1994, ONCOLOGY, V51, P70

[30] Intra-islet somatostatin regulates glucagon release via type 2 somatostatin receptors in rats [J].

Cejvan, K ;

Coy, DH ;

Efendic, S .

DIABETES, 2003, 52 (05) :1176-1181

← 1 2 3 4 5 6 7 8 9 10 →